Outcomes of MAIN-COMPARE: A 10-Year Follow-Up for a Historical Rivalry

Angioplasty and myocardial revascularization surgery have competed over the left main coronary artery for a long time. There may be many points of view involved in the interpretation of trial outcomes. While surgeons consider the left main coronary artery to be suitable for surgery (except when faced with surgical contraindications), interventional cardiologists see the left main coronary artery as feasible for angioplasty, with similar outcomes in hard endpoints such as mortality.

La cirugía parece superior a la angioplastia en pacientes jóvenesThe MAIN COMPARE (Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease) registry included 2240 patients with unprotected left main coronary artery disease who underwent angioplasty (n=1102) or myocardial revascularization surgery (n=1138) between 2000 and 2006.

 

Endpoints such as death; a composite of death, infarction, or stroke; and target-vessel revascularization were compared with the use of propensity scores.


Read also: TCT 2018 | MAIN COMPARE: Angioplasty vs. Surgery for Left Main Coronary Artery Disease at 10 Years.


The follow-up was at least 10 years for all patients (median 12.0 years).

 

In the global cohort, there were no significant differences after all adjustments in the risk of death and the composite endpoint between the groups at 10 years.

 

Unsurprisingly, the risk of target-vessel revascularization was significantly higher in the angioplasty group.


Read also: EXCEL Outcomes: PCI vs CABG in Patients with Prior Cerebrovascular disease.


Comparing only patients who received drug-eluting stents, there were no significant differences in the risk of death and the composite endpoints at 5 years. However, at that timepoint, curves started to separate in favor of myocardial revascularization surgery, in terms of both mortality (hazard ratio [HR]: 1.35; 95% confidence interval [CI]: 1.00 to 1.81) and the composite endpoints (HR: 1.46; 95% CI: 1.10 to 1.94).

 

Conclusion

In patients with left main coronary artery disease, angioplasty showed similar rates of mortality and combined endpoints, but a higher rate of revascularization, at 10 years. If we only analyze the outcomes of patients who received drug-eluting stents, after 5 years, surgery outperformed angioplasty in relation to all events, including mortality.

 

Original title: 10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease.

Reference: Duk-Woo Park et al. J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2813-2822.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...